English

THERAGENICS CORP

EDGAR

TGX Quarterly report (10-Q) · filed 2013-08-13

83 filing records in this dataset, filed from 1995-08-03 to 2013-08-13. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

20.3 million USD

2013 Q2 · USD

Exact inputs and evidence

Revenue: 20299000 USD Source

Operating margin

0.65%

2013 Q2 · %

Exact inputs and evidence

Operating Income: 131000 USD Source
Revenue: 20299000 USD Source

Operating cash flow

4.07 million USD

2013 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 3788000 USD Source
Operating Cash Flow: -277000 USD Source

Free cash flow

3.11 million USD

2013 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 3788000 USD Source
Operating Cash Flow: -277000 USD Source
Capital Expenditure: 953000 USD Source

Cash and cash equivalents: 16.9 million USD 2013-06-30 Source
Exact value

16852000 USD
Long-term debt including current maturities: 22 million USD 2011-09-30 Source
Exact value

22000000 USD
Shares outstanding: 34.7 thousand shares 2012-06-30 Source
Exact value

34730 shares

Reported share-count change

-99.90% · -33.9 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

33964000 shares · 2011-06-30· Source
34730 shares · 2012-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

79.2 million USD

2012-07-01 – 2013-06-30

Exact inputs and evidence

Revenue: 19916000 USD · 2012-07-01 – 2012-09-30 Source
Revenue: 19104000 USD · 2012-10-01 – 2012-12-31 Source
Revenue: 19873000 USD · 2013-01-01 – 2013-03-31 Source
Revenue: 20299000 USD · 2013-04-01 – 2013-06-30 Source

Net income

318 thousand USD

2012-07-01 – 2013-06-30

Exact inputs and evidence

Net income: 690000 USD · 2012-07-01 – 2012-09-30 Source
Net income: -323000 USD · 2012-10-01 – 2012-12-31 Source
Net income: -34000 USD · 2013-01-01 – 2013-03-31 Source
Net income: -15000 USD · 2013-04-01 – 2013-06-30 Source

Operating cash flow

12 million USD

2012-07-01 – 2013-06-30

Exact inputs and evidence

Operating cash flow: 9273000 USD · 2012-01-01 – 2012-09-30 Source
Operating cash flow: 4935000 USD · 2012-01-01 – 2012-06-30 Source
Operating cash flow: 13195000 USD · 2012-01-01 – 2012-12-31 Source
Operating cash flow: 9273000 USD · 2012-01-01 – 2012-09-30 Source
Operating cash flow: -277000 USD · 2013-01-01 – 2013-03-31 Source
Operating cash flow: 3788000 USD · 2013-01-01 – 2013-06-30 Source
Operating cash flow: -277000 USD · 2013-01-01 – 2013-03-31 Source

Capital expenditure

2.42 million USD

2012-07-01 – 2013-06-30

Exact inputs and evidence

Capital expenditure: 402000 USD · 2012-07-01 – 2012-09-30 Source
Capital expenditure: 1922000 USD · 2012-01-01 – 2012-12-31 Source
Capital expenditure: 1384000 USD · 2012-01-01 – 2012-09-30 Source
Capital expenditure: 527000 USD · 2013-01-01 – 2013-03-31 Source
Capital expenditure: 953000 USD · 2013-04-01 – 2013-06-30 Source

Free cash flow

9.63 million USD

2012-07-01 – 2013-06-30

Exact inputs and evidence

Operating cash flow: 9273000 USD · 2012-01-01 – 2012-09-30 Source
Operating cash flow: 4935000 USD · 2012-01-01 – 2012-06-30 Source
Operating cash flow: 13195000 USD · 2012-01-01 – 2012-12-31 Source
Operating cash flow: 9273000 USD · 2012-01-01 – 2012-09-30 Source
Operating cash flow: -277000 USD · 2013-01-01 – 2013-03-31 Source
Operating cash flow: 3788000 USD · 2013-01-01 – 2013-06-30 Source
Operating cash flow: -277000 USD · 2013-01-01 – 2013-03-31 Source
Capital expenditure: 402000 USD · 2012-07-01 – 2012-09-30 Source
Capital expenditure: 1922000 USD · 2012-01-01 – 2012-12-31 Source
Capital expenditure: 1384000 USD · 2012-01-01 – 2012-09-30 Source
Capital expenditure: 527000 USD · 2013-01-01 – 2013-03-31 Source
Capital expenditure: 953000 USD · 2013-04-01 – 2013-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2013-08-13.

Financial data available through: 2012-12-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2012-12-31
Operating income: 4 of 11 periods available· newest 2012-12-31
Net income: 4 of 11 periods available· newest 2012-12-31
Operating cash flow: 4 of 11 periods available· newest 2012-12-31
Capital expenditure: 4 of 11 periods available· newest 2012-12-31
Total assets: 4 of 11 periods available· newest 2012-12-31
Total liabilities: 4 of 11 periods available· newest 2012-12-31
Current assets: 4 of 11 periods available· newest 2012-12-31
Current liabilities: 4 of 11 periods available· newest 2012-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2012-12-31
Long-term debt including current maturities: 2 of 11 periods available· newest 2010-12-31
Shares outstanding: 2 of 11 periods available· newest 2011-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-0.2%

Prior period

USD 82.73 million

2011-01-01 – 2011-12-31
Current period

USD 82.56 million

2012-01-01 – 2012-12-31

Exact inputs and evidence

82559000 − 82730000 = -171000 USD

82730000 USD · 2011-01-01 – 2011-12-31
Inspect prior input Prior source
82559000 USD · 2012-01-01 – 2012-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · THERAGENICS CORP · 2012-12-31 THERAGENICS CORP (edgar:795551) Year-over-year change in Revenue: -171000 USD Concept: fundies:Revenue Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/795551?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 82559000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#127106 Filing: 000118811213000590 Input fundies:Revenue: 82730000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#125940 Filing: 000118811213000590
The citation records this snapshot. The page link may show a newer release later.
Net income
-30.2%

Prior period

USD 3.06 million

2011-01-01 – 2011-12-31
Current period

USD 2.14 million

2012-01-01 – 2012-12-31

Exact inputs and evidence

2139000 − 3064000 = -925000 USD

3064000 USD · 2011-01-01 – 2011-12-31
Inspect prior input Prior source
2139000 USD · 2012-01-01 – 2012-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · THERAGENICS CORP · 2012-12-31 THERAGENICS CORP (edgar:795551) Year-over-year change in Net income: -925000 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/795551?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 2139000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#138328 Filing: 000118811213000590 Input fundies:NetIncome: 3064000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#137558 Filing: 000118811213000590
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+116.7%

Prior period

USD 6.09 million

2011-01-01 – 2011-12-31
Current period

USD 13.2 million

2012-01-01 – 2012-12-31

Exact inputs and evidence

13195000 − 6090000 = 7105000 USD

6090000 USD · 2011-01-01 – 2011-12-31
Inspect prior input Prior source
13195000 USD · 2012-01-01 – 2012-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · THERAGENICS CORP · 2012-12-31 THERAGENICS CORP (edgar:795551) Year-over-year change in Operating cash flow: 7105000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/795551?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 13195000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#183682 Filing: 000118811213000590 Input fundies:OperatingCashFlow: 6090000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#183464 Filing: 000118811213000590
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-5.1%

Prior period

USD 2.03 million

2011-01-01 – 2011-12-31
Current period

USD 1.92 million

2012-01-01 – 2012-12-31

Exact inputs and evidence

1922000 − 2026000 = -104000 USD

2026000 USD · 2011-01-01 – 2011-12-31
Inspect prior input Prior source
1922000 USD · 2012-01-01 – 2012-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · THERAGENICS CORP · 2012-12-31 THERAGENICS CORP (edgar:795551) Year-over-year change in Capital expenditure: -104000 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/795551?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1922000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#185181 Filing: 000118811213000590 Input fundies:CapitalExpenditure: 2026000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#184541 Filing: 000118811213000590
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2012 2012-01-01 – 2012-12-31

Revenue USD 82.56 million 100% of revenue
Cost of revenue USD 52.02 million 63% of revenue
Operating expenses USD 26.78 million 32% of revenue
Operating income USD 3.77 million 4.6% of revenue
Tax, interest and other Derived USD 1.63 million 2% of revenue
Net income USD 2.14 million 2.6% of revenue

Cash

Operating cash flow USD 13.2 million 16% of revenue
Capital expenditure USD 1.92 million 2.3% of revenue
Free cash flow Derived USD 11.27 million 14% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2009 93%
2010 95%
2011 93%
2012 95%

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2009 2009-01-01 – 2009-12-31	78326000	72577000 Derived	5749000	2674000 Derived	3075000	6607000 Derived	Source 2009-01-01 – 2009-12-31: 78326000 USD Inspect Revenue Open source 2009-01-01 – 2009-12-31: 5749000 USD Inspect Operating Income Open source 2009-01-01 – 2009-12-31: 3075000 USD Inspect Net Income Open source 2009-01-01 – 2009-12-31: 11587000 USD Inspect Operating Cash Flow Open source 2009-01-01 – 2009-12-31: 4980000 USD Inspect Capital Expenditure Open source
2010 2010-01-01 – 2010-12-31	82184000	78298000 Derived	3886000	1816000 Derived	2070000	-1179000 Derived	Source 2010-01-01 – 2010-12-31: 82184000 USD Inspect Revenue Open source 2010-01-01 – 2010-12-31: 3886000 USD Inspect Operating Income Open source 2010-01-01 – 2010-12-31: 2070000 USD Inspect Net Income Open source 2010-01-01 – 2010-12-31: 7886000 USD Inspect Operating Cash Flow Open source 2010-01-01 – 2010-12-31: 9065000 USD Inspect Capital Expenditure Open source
2011 2011-01-01 – 2011-12-31	82730000	77234000 Derived	5496000	2432000 Derived	3064000	4064000 Derived	Source 2011-01-01 – 2011-12-31: 82730000 USD Inspect Revenue Open source 2011-01-01 – 2011-12-31: 5496000 USD Inspect Operating Income Open source 2011-01-01 – 2011-12-31: 3064000 USD Inspect Net Income Open source 2011-01-01 – 2011-12-31: 6090000 USD Inspect Operating Cash Flow Open source 2011-01-01 – 2011-12-31: 2026000 USD Inspect Capital Expenditure Open source
2012 2012-01-01 – 2012-12-31	82559000	78792000 Derived	3767000	1628000 Derived	2139000	11273000 Derived	Source 2012-01-01 – 2012-12-31: 82559000 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: 3767000 USD Inspect Operating Income Open source 2012-01-01 – 2012-12-31: 2139000 USD Inspect Net Income Open source 2012-01-01 – 2012-12-31: 13195000 USD Inspect Operating Cash Flow Open source 2012-01-01 – 2012-12-31: 1922000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 82.6M 2012

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20092009-12-31	Revenue	78326000	Revenue: 78326000 Open source
20102010-12-31	Revenue	82184000	Revenue: 82184000 Open source
20112011-12-31	Revenue	82730000	Revenue: 82730000 Open source
20122012-12-31	Revenue	82559000	Revenue: 82559000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-0.2% 2012

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20092009-12-31	Year over year	No prior comparable period	Revenue: 78326000 Open source
20102010-12-31	Year over year	4.9%	Revenue: 82184000 Open source Revenue: 78326000 Open source
20112011-12-31	Year over year	0.7%	Revenue: 82730000 Open source Revenue: 82184000 Open source
20122012-12-31	Year over year	-0.2%	Revenue: 82559000 Open source Revenue: 82730000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 4.6% 2012

Net margin 2.6% 2012

Free cash flow margin 13.7% 2012

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20092009-12-31	Operating margin	7.3%	Operating Income: 5749000 Open source Revenue: 78326000 Open source
20102010-12-31	Operating margin	4.7%	Operating Income: 3886000 Open source Revenue: 82184000 Open source
20112011-12-31	Operating margin	6.6%	Operating Income: 5496000 Open source Revenue: 82730000 Open source
20122012-12-31	Operating margin	4.6%	Operating Income: 3767000 Open source Revenue: 82559000 Open source
20092009-12-31	Net margin	3.9%	Net Income: 3075000 Open source Revenue: 78326000 Open source
20102010-12-31	Net margin	2.5%	Net Income: 2070000 Open source Revenue: 82184000 Open source
20112011-12-31	Net margin	3.7%	Net Income: 3064000 Open source Revenue: 82730000 Open source
20122012-12-31	Net margin	2.6%	Net Income: 2139000 Open source Revenue: 82559000 Open source
20092009-12-31	Free cash flow margin	8.4%	Revenue: 78326000 Open source Operating Cash Flow: 11587000 Open source Capital Expenditure: 4980000 Open source
20102010-12-31	Free cash flow margin	-1.4%	Revenue: 82184000 Open source Operating Cash Flow: 7886000 Open source Capital Expenditure: 9065000 Open source
20112011-12-31	Free cash flow margin	4.9%	Revenue: 82730000 Open source Operating Cash Flow: 6090000 Open source Capital Expenditure: 2026000 Open source
20122012-12-31	Free cash flow margin	13.7%	Revenue: 82559000 Open source Operating Cash Flow: 13195000 Open source Capital Expenditure: 1922000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 13.2M 2012

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20092009-12-31	Operating cash flow	11587000	Operating Cash Flow: 11587000 Open source
20102010-12-31	Operating cash flow	7886000	Operating Cash Flow: 7886000 Open source
20112011-12-31	Operating cash flow	6090000	Operating Cash Flow: 6090000 Open source
20122012-12-31	Operating cash flow	13195000	Operating Cash Flow: 13195000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 11.3M 2012

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20092009-12-31	Free cash flow	6607000	Operating Cash Flow: 11587000 Open source Capital Expenditure: 4980000 Open source
20102010-12-31	Free cash flow	-1179000	Operating Cash Flow: 7886000 Open source Capital Expenditure: 9065000 Open source
20112011-12-31	Free cash flow	4064000	Operating Cash Flow: 6090000 Open source Capital Expenditure: 2026000 Open source
20122012-12-31	Free cash flow	11273000	Operating Cash Flow: 13195000 Open source Capital Expenditure: 1922000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

27.2% 2012

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20092009-12-31	Liabilities / assets	33.1%	Total Liabilities: 38455000 Open source Total Assets: 116108000 Open source
20102010-12-31	Liabilities / assets	30.3%	Total Liabilities: 34908000 Open source Total Assets: 115187000 Open source
20112011-12-31	Liabilities / assets	27.4%	Total Liabilities: 31696000 Open source Total Assets: 115818000 Open source
20122012-12-31	Liabilities / assets	27.2%	Total Liabilities: 28798000 Open source Total Assets: 105725000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

11.05× 2012

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20092009-12-31	Current assets / current liabilities	7.64×	Current Assets: 68559000 Open source Current Liabilities: 8972000 Open source
20102010-12-31	Current assets / current liabilities	7.37×	Current Assets: 66066000 Open source Current Liabilities: 8968000 Open source
20112011-12-31	Current assets / current liabilities	2.44×	Current Assets: 71738000 Open source Current Liabilities: 29448000 Open source
20122012-12-31	Current assets / current liabilities	11.05×	Current Assets: 61548000 Open source Current Liabilities: 5571000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2009 2009-01-01 – 2009-12-31	USD 3.08 million Exact value Exact value: 3075000 USD 2009-01-01 – 2009-12-31: 3075000 USD Inspect Net Income Open source Share or cite Citation for Net Income · THERAGENICS CORP · 2009-12-31 THERAGENICS CORP (edgar:795551) Net Income: 3075000 USD Concept: fundies:NetIncome Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/795551/explain?concept=fundies%3ANetIncome&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:NetIncome: 3075000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811212000594/tgx-20111231.xml#22143 Filing: 000118811212000594 The citation records this snapshot. The page link may show a newer release later.	USD 11.59 million Exact value Exact value: 11587000 USD 2009-01-01 – 2009-12-31: 11587000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · THERAGENICS CORP · 2009-12-31 THERAGENICS CORP (edgar:795551) Operating Cash Flow: 11587000 USD Concept: fundies:OperatingCashFlow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/795551/explain?concept=fundies%3AOperatingCashFlow&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 11587000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811212000594/tgx-20111231.xml#19372 Filing: 000118811212000594 The citation records this snapshot. The page link may show a newer release later.	USD 4.98 million Exact value Exact value: 4980000 USD 2009-01-01 – 2009-12-31: 4980000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · THERAGENICS CORP · 2009-12-31 THERAGENICS CORP (edgar:795551) Capital Expenditure: 4980000 USD Concept: fundies:CapitalExpenditure Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/795551/explain?concept=fundies%3ACapitalExpenditure&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4980000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811212000594/tgx-20111231.xml#23223 Filing: 000118811212000594 The citation records this snapshot. The page link may show a newer release later.	USD 6.61 million Calculation and evidence 11587000 − 4980000 USD Exact free cash flow: 6607000 USD 2009-01-01 – 2009-12-31: 11587000 USD · Inspect Operating Cash Flow · Source 2009-01-01 – 2009-12-31: 4980000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · THERAGENICS CORP · 2009-12-31 THERAGENICS CORP (edgar:795551) Free cash flow: 6607000 USD Concept: free-cash-flow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/795551?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 11587000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811212000594/tgx-20111231.xml#19372 Filing: 000118811212000594 Input fundies:CapitalExpenditure: 4980000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811212000594/tgx-20111231.xml#23223 Filing: 000118811212000594 The citation records this snapshot. The page link may show a newer release later.
2010 2010-01-01 – 2010-12-31	USD 2.07 million Exact value Exact value: 2070000 USD 2010-01-01 – 2010-12-31: 2070000 USD Inspect Net Income Open source Share or cite Citation for Net Income · THERAGENICS CORP · 2010-12-31 THERAGENICS CORP (edgar:795551) Net Income: 2070000 USD Concept: fundies:NetIncome Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/795551/explain?concept=fundies%3ANetIncome&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:NetIncome: 2070000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#136787 Filing: 000118811213000590 The citation records this snapshot. The page link may show a newer release later.	USD 7.89 million Exact value Exact value: 7886000 USD 2010-01-01 – 2010-12-31: 7886000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · THERAGENICS CORP · 2010-12-31 THERAGENICS CORP (edgar:795551) Operating Cash Flow: 7886000 USD Concept: fundies:OperatingCashFlow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/795551/explain?concept=fundies%3AOperatingCashFlow&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 7886000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#183246 Filing: 000118811213000590 The citation records this snapshot. The page link may show a newer release later.	USD 9.07 million Exact value Exact value: 9065000 USD 2010-01-01 – 2010-12-31: 9065000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · THERAGENICS CORP · 2010-12-31 THERAGENICS CORP (edgar:795551) Capital Expenditure: 9065000 USD Concept: fundies:CapitalExpenditure Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/795551/explain?concept=fundies%3ACapitalExpenditure&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9065000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#183901 Filing: 000118811213000590 The citation records this snapshot. The page link may show a newer release later.	−USD 1.18 million Calculation and evidence 7886000 − 9065000 USD Exact free cash flow: -1179000 USD 2010-01-01 – 2010-12-31: 7886000 USD · Inspect Operating Cash Flow · Source 2010-01-01 – 2010-12-31: 9065000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · THERAGENICS CORP · 2010-12-31 THERAGENICS CORP (edgar:795551) Free cash flow: -1179000 USD Concept: free-cash-flow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/795551?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 7886000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#183246 Filing: 000118811213000590 Input fundies:CapitalExpenditure: 9065000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#183901 Filing: 000118811213000590 The citation records this snapshot. The page link may show a newer release later.
2011 2011-01-01 – 2011-12-31	USD 3.06 million Exact value Exact value: 3064000 USD 2011-01-01 – 2011-12-31: 3064000 USD Inspect Net Income Open source Share or cite Citation for Net Income · THERAGENICS CORP · 2011-12-31 THERAGENICS CORP (edgar:795551) Net Income: 3064000 USD Concept: fundies:NetIncome Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/795551/explain?concept=fundies%3ANetIncome&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:NetIncome: 3064000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#137558 Filing: 000118811213000590 The citation records this snapshot. The page link may show a newer release later.	USD 6.09 million Exact value Exact value: 6090000 USD 2011-01-01 – 2011-12-31: 6090000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · THERAGENICS CORP · 2011-12-31 THERAGENICS CORP (edgar:795551) Operating Cash Flow: 6090000 USD Concept: fundies:OperatingCashFlow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/795551/explain?concept=fundies%3AOperatingCashFlow&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 6090000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#183464 Filing: 000118811213000590 The citation records this snapshot. The page link may show a newer release later.	USD 2.03 million Exact value Exact value: 2026000 USD 2011-01-01 – 2011-12-31: 2026000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · THERAGENICS CORP · 2011-12-31 THERAGENICS CORP (edgar:795551) Capital Expenditure: 2026000 USD Concept: fundies:CapitalExpenditure Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/795551/explain?concept=fundies%3ACapitalExpenditure&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2026000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#184541 Filing: 000118811213000590 The citation records this snapshot. The page link may show a newer release later.	USD 4.06 million Calculation and evidence 6090000 − 2026000 USD Exact free cash flow: 4064000 USD 2011-01-01 – 2011-12-31: 6090000 USD · Inspect Operating Cash Flow · Source 2011-01-01 – 2011-12-31: 2026000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · THERAGENICS CORP · 2011-12-31 THERAGENICS CORP (edgar:795551) Free cash flow: 4064000 USD Concept: free-cash-flow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/795551?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 6090000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#183464 Filing: 000118811213000590 Input fundies:CapitalExpenditure: 2026000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#184541 Filing: 000118811213000590 The citation records this snapshot. The page link may show a newer release later.
2012 2012-01-01 – 2012-12-31	USD 2.14 million Exact value Exact value: 2139000 USD 2012-01-01 – 2012-12-31: 2139000 USD Inspect Net Income Open source Share or cite Citation for Net Income · THERAGENICS CORP · 2012-12-31 THERAGENICS CORP (edgar:795551) Net Income: 2139000 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/795551/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: 2139000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#138328 Filing: 000118811213000590 The citation records this snapshot. The page link may show a newer release later.	USD 13.2 million Exact value Exact value: 13195000 USD 2012-01-01 – 2012-12-31: 13195000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · THERAGENICS CORP · 2012-12-31 THERAGENICS CORP (edgar:795551) Operating Cash Flow: 13195000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/795551/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 13195000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#183682 Filing: 000118811213000590 The citation records this snapshot. The page link may show a newer release later.	USD 1.92 million Exact value Exact value: 1922000 USD 2012-01-01 – 2012-12-31: 1922000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · THERAGENICS CORP · 2012-12-31 THERAGENICS CORP (edgar:795551) Capital Expenditure: 1922000 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/795551/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1922000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#185181 Filing: 000118811213000590 The citation records this snapshot. The page link may show a newer release later.	USD 11.27 million Calculation and evidence 13195000 − 1922000 USD Exact free cash flow: 11273000 USD 2012-01-01 – 2012-12-31: 13195000 USD · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 1922000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · THERAGENICS CORP · 2012-12-31 THERAGENICS CORP (edgar:795551) Free cash flow: 11273000 USD Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T13:38:45Z Snapshot: adc86e137c1d5c1728af1c8dd6f7a4365ff3883d721ec927eeb3c935682b348d Dimensions: Consolidated View: https://fundies.io/companies/edgar/795551?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 13195000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#183682 Filing: 000118811213000590 Input fundies:CapitalExpenditure: 1922000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/795551/000118811213000590/tgx-20121231.xml#185181 Filing: 000118811213000590 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

83 filings · 1,276 latest values · 1,276 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000795551, 795551, TGX, edgar:795551, tgx

Also known as THERAGENICS CORP

THERAGENICS CORP

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2012 2012-01-01 – 2012-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation